ONCOBEAM CRC RAS KIT
Clinically actionable information with a simple blood draw
- Extensive 34 mutation KRAS and NRAS assay
- A more rapid turnaround time from biopsy to result
- Proven BEAMing technologie
Go beyond KRAS – The All‐RAS‐Panel
Our understanding of the important RAS mutations in CRC has evolved over time. In 2008, KRAS mutations in Codons12 and 13 were the only mutations considered important in determining the appropriate therapy for metastatic colorectal cancer patients. Since that time, recent clinical studies have shown that the detection of additional mutations in KRAS and NRAS codons should also be considered in determining patient eligibility for targeted anti‐EGFR therapies.
A meta‐analysis of randomized, controlled trials (RCT) was conducted on the prevalence of RAS mutations in mCRC. Nine RCTs comprising a total of almost 6,000 participants were evaluated for both KRAS Exon 2 and new KRAS and NRAS mutations. The conclusion of the analysis is that patients with tumors exhibiting one of the new RAS mutations are unlikely to significantly benefit from anti‐EGFR therapy in mCRC.
In 2015, guidelines were updated to recommend expanded RAS testing prior to use of an anti‐EGFR treatment4‐6. The inclusion of low frequency KRAS and NRAS mutations in Exons 2, 3 and 4 formed the basis for our comprehensive OncoBEAM RAS CRC kit (RUO).